Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2OSdNcY
via IFTTT